As­traZeneca broad­ens pres­ence in Chi­na, promis­ing $8B+ to Har­bour and Syneron

As­traZeneca is fur­ther in­vest­ing in Chi­na, open­ing an R&D cen­ter in Bei­jing and ink­ing a pair of ma­jor­ly back­loaded R&D deals with Chi­nese drug de­vel­op­ers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER